Earnings summaries and quarterly performance for Rezolute.
Executive leadership at Rezolute.
Board of directors at Rezolute.
Research analysts covering Rezolute.
Recent press releases and 8-K filings for RZLT.
Rezolute Under Investigation Following Failed Phase 3 Clinical Trial Results
RZLT
Legal Proceedings
New Projects/Investments
- Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc..
- This investigation follows a sharp decline in Rezolute shares on December 11, 2025, due to disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug.
- The clinical trial, which aimed to treat congenital hyperinsulinism, failed to meet both its primary and key secondary endpoints.
- The highest dose of ersodetug did not demonstrate statistically significant reductions in hypoglycemia events versus placebo.
2 days ago
Rezolute Faces Legal Investigation Following Clinical Trial Failure
RZLT
Legal Proceedings
- Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. (NASDAQ: RZLT).
- The investigation stems from a sharp decline in Rezolute's stock on December 11, 2025, following disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug.
- The clinical trial failed to meet both its primary and key secondary endpoints, as the highest dose of ersodetug did not show statistically significant reductions in hypoglycemia events compared to placebo.
- On December 11, 2025, RZLT shares collapsed approximately 85–90%, from around $10.94 to an intraday low near $0.90.
Feb 19, 2026, 2:51 PM
Rezolute Reports Q2 FY26 Financial Results and Mixed Phase 3 Study Outcomes
RZLT
Earnings
Layoffs
New Projects/Investments
- Rezolute, Inc. reported a net loss of $22.8 million for the second quarter of fiscal 2026, compared to a net loss of $15.7 million for the same period a year ago.
- Cash, cash equivalents, and investments in marketable securities were $132.9 million as of December 31, 2025, a decrease from $167.9 million as of June 30, 2025.
- The sunRIZE Phase 3 study for ersodetug in congenital hyperinsulinism (HI) did not meet its primary or key secondary endpoints. The company plans to meet with the FDA to determine next steps for the program.
- The upLIFT Phase 3 study for tumor HI is ongoing, with topline results expected in the second half of 2026.
- Aggregate data from the historical Expanded Access Program for tumor HI showed that 75% of patients achieved a complete discontinuation of IV dextrose/TPN.
Feb 12, 2026, 9:13 PM
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Business Update
RZLT
Earnings
New Projects/Investments
Guidance Update
- Rezolute reported cash, cash equivalents and investments in marketable securities of $132.9 million as of December 31, 2025, a decrease from $167.9 million as of June 30, 2025, and a net loss of $22.8 million for the second quarter of fiscal 2026.
- The Phase 3 sunRIZE study for congenital hyperinsulinism (HI) did not meet its primary or key secondary endpoints in December 2025, though pharmacologic activity was observed, and the company plans to meet with the FDA to determine next steps.
- The Phase 3 upLIFT study for tumor HI is ongoing with enrollment underway, and topline results are expected in the second half of 2026.
Feb 12, 2026, 9:05 PM
Rezolute Shares Plummet 90% After Lead Asset Trial Failure
RZLT
Legal Proceedings
Profit Warning
New Projects/Investments
- On December 11, 2025, Rezolute, Inc. shares cratered as much as 90% during intraday trading after the company announced the failure of its Phase 3 sunRIZE trial for ersodetug.
- The trial for ersodetug, a potential treatment for hypoglycemia caused by hyperinsulinism, did not meet its primary or secondary endpoints.
- Following the news, national shareholders rights firm Hagens Berman opened an investigation into whether Rezolute may have previously misled investors about the drug's efficacy and commercial prospects.
- Analysts reacted by slashing Rezolute's rating from outperform to neutral and its price target from $12 to $1.
Feb 9, 2026, 8:19 PM
Rezolute faces legal investigation following clinical trial failure
RZLT
Legal Proceedings
Demand Weakening
- Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc..
- This investigation follows a sharp decline in Rezolute shares on December 11, 2025, due to disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug.
- The trial failed to meet both its primary and key secondary endpoints, with the highest dose of ersodetug not showing statistically significant reductions in hypoglycemia events versus placebo.
Feb 4, 2026, 12:44 AM
Rezolute faces investigation after clinical trial failure
RZLT
Legal Proceedings
New Projects/Investments
- Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. (RZLT).
- This investigation follows a sharp decline in Rezolute shares on December 11, 2025, due to disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug.
- The clinical trial for ersodetug, Rezolute's lead drug candidate for treating congenital hyperinsulinism, failed to meet both its primary and key secondary endpoints.
- The highest dose of ersodetug did not demonstrate statistically significant reductions in hypoglycemia events compared to placebo.
Jan 23, 2026, 3:33 PM
Rezolute Faces Legal Investigation Following Clinical Trial Failure
RZLT
Legal Proceedings
- Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. (NASDAQ: RZLT) on behalf of investors who suffered significant losses.
- This investigation follows a sharp decline in Rezolute's shares on December 11, 2025, after disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug.
- The clinical trial failed to meet both its primary and key secondary endpoints, as the highest dose of ersodetug did not show statistically significant reductions in hypoglycemia events compared to placebo.
- During intraday trading, RZLT stock collapsed from approximately $10.94 to an intraday low near $0.90, representing an approximate 85–90% drop.
Jan 17, 2026, 3:49 PM
Rezolute Shares Plummet After Drug Trial Failure
RZLT
Legal Proceedings
New Projects/Investments
- On December 11, 2025, Rezolute, Inc. (RZLT) shares crashed as much as 90% during intraday trading following the announcement of the failure of its Phase 3 sunRIZE trial for ersodetug.
- The drug, ersodetug, intended to treat hypoglycemia caused by hyperinsulinism, did not meet its primary or secondary endpoints in the trial.
- The news prompted national shareholders rights firm Hagens Berman to open an investigation into whether Rezolute misled investors about erso's efficacy and commercial prospects.
- Analysts reacted swiftly, with one reportedly slashing Rezolute's rating from outperform to neutral and the price target from $12 to $1.
Jan 14, 2026, 4:58 PM
Rezolute Faces Investigation Following Failed Clinical Trial Results
RZLT
Legal Proceedings
Demand Weakening
Product Launch
- Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. (NASDAQ: RZLT).
- This investigation follows a sharp decline in Rezolute shares on December 11, 2025, due to disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug.
- The clinical trial for ersodetug, Rezolute's lead drug candidate for treating congenital hyperinsulinism, failed to meet both its primary and key secondary endpoints.
- The highest dose of ersodetug did not show statistically significant reductions in hypoglycemia events compared to placebo.
Jan 8, 2026, 6:12 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more